Lumos Pharma (LUMO) Stock Price, News & Analysis

Company Overview

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

Key Stats

• Today's Range: $4.33 to $4.39
• 50-Day Range: $4.30 to $4.41
• 52-Week Range: $1.37 to $4.58
• Volume: 481,600 shs
• Average Volume: 57,302 shs
• Market Capitalization: $37.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.63
• Consensus Rating: Buy

LUMO Stock Analysis - Frequently Asked Questions

How were Lumos Pharma's earnings last quarter?

Lumos Pharma, Inc. (NASDAQ:LUMO) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by $0.34. The firm had revenue of $0.73 million for the quarter, compared to analysts' expectations of $0.50 million. Lumos Pharma had a negative net margin of 1,583.49% and a negative trailing twelve-month return on equity of 233.03%.

Who are Lumos Pharma's major shareholders?

Top institutional investors of Lumos Pharma include Concourse Financial Group Securities Inc.. Insiders that own company stock include John C Mckew, Thomas A Raffin and Richard J Hawkins.
View institutional ownership trends.

What other stocks do shareholders of Lumos Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Pharma investors own include uniQure (QURE), Clean Energy Fuels (CLNE), ACADIA Pharmaceuticals (ACAD), Bicycle Therapeutics (BCYC), Curaleaf (CURLF), Paycom Software (PAYC) and Vale (VALE).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LUMO
• CUSIP: N/A
• CIK: 1126234
• Web: www.lumos-pharma.com
• Phone: (512) 215-2630
• Fax: 515-296-3520
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.63
• High Stock Price Target: $13.00
• Low Stock Price Target: $4.25
• Potential Upside/Downside: +98.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-34,030,000.00
• Net Margins: -1,583.49%
• Pretax Margin: -1,583.49%
• Return on Equity: -233.03%
• Return on Assets: -129.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.66
• Quick Ratio: 2.66

Sales & Book Value

• Annual Sales: $2.21 million
• Price / Sales: 17.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.45 per share
• Price / Book: 1.26

Miscellaneous

• Outstanding Shares: 8,649,000
• Free Float: 6,452,000
• Market Cap: $37.54 million
• Optionable: Not Optionable
• Beta: 0.74